Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection

Mini Rev Med Chem. 2012 Aug;12(9):890-904. doi: 10.2174/138955712800959062.

Abstract

Concurrent infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients positive for human immunodeficiency virus (HIV) is relatively common. The treatment of co-infected individuals is rather complex because the anti-viral therapy may be associated with drug-resistance, hepatotoxicity and lack of response. Herein, we present a summary of the available compounds and the recent recommendations concerning the therapeutic management of HIV/HBV and HIV/HCV co-infections.

Publication types

  • Review

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • Antiviral Agents / therapeutic use*
  • Coinfection
  • Disease Management
  • Drug Administration Schedule
  • Drug Resistance, Viral / drug effects
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / drug effects
  • HIV-1 / physiology
  • Hepacivirus / drug effects
  • Hepacivirus / physiology
  • Hepatitis B / drug therapy*
  • Hepatitis B / virology
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / physiology
  • Hepatitis C / drug therapy*
  • Hepatitis C / virology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Recombinant Proteins / therapeutic use

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins